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78The epidemiology of autoimmune liver disease (AILD) is challenging to study because of the
diseases’ rarity and because of cohort selection bias. Increased incidence farther from the
Equator has been reported for multiple sclerosis, another autoimmune disease. We assessed
the incidence of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and




83We performed a retrospective cohort study using anonymized UK primary care records from
January 1, 2002, to 2016-05-10. All adults without a baseline diagnosis of AILD were included
and followed up until the first occurrence of an AILD diagnosis, death, or they left the database.










95The cohort included 8,590,421 records with 53.3 3 107 years of follow-up evaluation from 694
practices. There were 1314 incident cases of PBC, 396 of PSC, and 1034 of AIH. Crude incidences
were as follows: PBC, 2.47 (95% CI, 2.34–2.60); PSC, 0.74 (95% CI, 0.67–0.82); and AIH, 1.94
(95% CI, 1.83–2.06) per 100,000 per year. PBC incidence correlated with female sex, smoking,
and deprivation; PSC incidence correlated with male sex and nonsmoking; AIH incidence
correlated with female sex and deprivation. A more northerly latitude was associated strongly
with incidence of PBC: 2.16 (95% CI, 1.79–2.60) to 4.86 (95% CI, 3.93–6.00) from 50N to 57N
(P [ .002) and incidence of AIH: 2.00 (95% CI, 1.65–2.43) to 3.28 (95% CI, 2.53–4.24) (P [
.003), but not incidence of PSC: 0.82 (95% CI, 0.60–1.11) to 1.02 (95% CI, 0.64–1.61) (P[ .473).
Incidence after adjustment for age, sex, smoking, and deprivation status showed similar posi-
tive correlations for PBC and AIH with latitude, but not PSC. Incident AIH cases were younger at
greater latitude.96
97CONCLUSIONS:98We describe an association in the United Kingdom between increased latitude and the inci-
dence of PBC and AIH that requires both confirmation and explanation.99100
101Keywords: Autoimmune Liver Disease; Latitude; Primary Biliary Cholangitis; Primary Sclerosing Cholangitis; Autoimmune
Hepatitis.102Abbreviations used in this paper: AIH, autoimmune hepatitis; AILD, auto-
immune liver disease; IQR, interquartile range; MS, multiple sclerosis;
PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis;
THIN, The Health Improvement Network.
© 2021 by the AGA Institute. Published by Elsevier Inc. This is an open

















116The 3 major autoimmune liver diseases (AILDs),primary biliary cholangitis (PBC), primary scle-
rosing cholangitis (PSC), and autoimmune hepatitis
(AIH), represent significant causes of liver morbidity and
mortality whose etiopathogenesis is incompletely
understood.1–3 Although individually uncommon,
together they account for a significant proportion of
elective liver transplantation,4 and the incidence and
prevalence appear to be increasing.5–8
To date, genetic association studies only have been
able to explain a minority of the risk for the 3 AILDs,
suggesting a significant role for environmental factors.9
A number of environmental factors have been identifiedA 5.6.0 DTD  YJCGH57705_proof  1as associated with risk of AILD including urinary tract
infections, nail polish use, hair dye use, smoking, and
deprivation in PBC10–14; smoking as a negative risk
factor in PSC15,16; and various drug exposures in8 February 2021  6:24 pm  ce DVC
Q16
What You Need to Know
Background
Disease risk in primary biliary cholangitis, primary
sclerosing cholangitis, and autoimmune hepatitis are
insufficiently explained by genetic factors. In other
autoimmune diseases such as multiple sclerosis,
geographic latitude correlates with disease risk.
Findings
We show a novel association between increased
geographic latitude and disease incidence of primary
biliary cholangitis and autoimmune hepatitis, but not
primary sclerosing cholangitis, in a large UK primary
care population.
Implications for patient care
Although these findings require confirmation in
other populations, they inform Q13further exploration of
pathogenic mechanisms influencing disease risk
such as vitamin D deficiency.



















































































199AIH.3,17,18 However, even in aggregate, these factors
appear insufficient to explain variations in individual
disease risk.9
Latitude has been proposed as a risk factor for
AILDs because of its link to vitamin D status and in
turn the link between vitamin D status and risk of
autoimmunity.19–23 TH1 T-cell activation and B-cell
activation are implicated in each of the AILDs, and
activation is regulated negatively by physiological
concentrations of vitamin D.1–3,22 The association be-
tween the neurologic autoimmune disease multiple
sclerosis (MS) and latitude is well established.24,25 For
type 1 diabetes, childhood hypovitaminosis D has been
associated with increased disease risk.26 By analogy,
similar associations with latitude exposure have been
shown in other autoimmune conditions and latitude
has been suggested as a target for investigation among
the AILDs, but to date such an assessment has not
been performed.21,27
In this study we investigated the relationship be-
tween latitude and incidence of AILD in a large UK pri-
mary care database with established generalizability to
the national population.28 We also describe disease
prevalence and assess disease associations with age, sex,





















Study Design and Population
A retrospective cohort study was performed using the
pseudonymized primary care health records contained in
The Health Improvement Network (THIN) database be-
tween January 1, 2002, and 2016-05-10.29 THIN is a UK-
based primary care database containing routinely
collected electronic patient records. At each consultation,
general practitioners record details of the medical
encounter, including diagnosis. Demographic details such
as age, sex, and linked deprivation scores also form part
of the electronic record. Deprivation is based on a com-
bination of scores for home ownership, car ownership,
unemployment, and household overcrowding, and is
adjusted so that the country is represented as 5 equally






Patients of all ages registered with a practice








Patients with a previous diagnosis of AILD at baseline
were excluded. Patients with potential overlap of auto-
immune liver diseases were excluded (see later).FLA 5.6.0 DTD  YJCGH57705_proof  1Follow-Up Evaluation
Patients were followed up until death, leaving a
contributing practice, the date that a practice stopped
contributing to THIN, or the end of the study period,
whichever was latest.Exposure
Latitude was measured by geocoding latitude from the
postal code of the general practice concerned. This was
performed by THIN to avoid identification of individual
practices; the locations of individual practices were not
available to the authors. Latitude was rounded down to the
nearest integer. Because of the small population residing in
the 58 latitude band, the residents at 58 were combined
with the residents at 57 for analysis. Townsend30 quintiles
were calculated from the postcode of place of residence by
THIN. Covariable data on age, sex, smoking status, and
ethnicity were collected from general practice records. The
most recently submitted data in each category at the end of
the follow-up period were used in each case.Outcomes
Diagnoses of AILDs were defined using diagnostic
codes (Supplementary Table 1). For PBC and PSC, a
single diagnostic code specific to the respective condition
was identified; for AIH, a combination of 3 potential
codes validated in a previous study was used.31 Of note,
in contrast to the International Classification of Diseases
system of diagnostic codes, the Read code system used in
UK general practice contains a specific term for PSC. For
use as positive and negative controls of conditions with8 February 2021  6:24 pm  ce DVC
Q18
Q19















































































































































































Figure 1. Incidence of autoimmune liver disease by latitude. Top row: Plots denote crude incidence of (A) primary biliary
cholangitis (PBC), (B) primary sclerosing cholangitis (PSC), and (C) autoimmune hepatitis (AIH). (D–F) Bottom row: Plots denote
adjusted incidence after adjustment for sex, age, smoking status, and Townsend30 deprivation quintile. For PBC and AIH there
was a significant increase in incidence at more northerly latitudes both before and after adjustment; for PSC a significant
correlation was not present.












































































































340and without published associations with latitude, cases
of MS and hypertension were examined using standard
diagnostic codes (Supplementary Table 1).
Cases with 2 or more lifetime diagnoses of different
AILDs (ie, cases of possible autoimmune overlap) were
not considered to represent incident disease for any
AILD diagnosis. Cases were considered incident if the
date of their first recording was more than 1 year after
the individual’s registration at the practice concerned,
and also 1 year after the practice had achieved accept-
able mortality reporting.32 This was to prevent pre-
existing diagnoses appearing incident in new registra-
tions at a particular general practice.33
Data regarding the Townsend30 deprivation quintile
were provided by THIN and derived from the postal code
of the patient’s residence. Latitude bands were provided
by THIN at special request and were derived from the
practice postal code.
All data used were those most recent at the end of the








All data were analyzed using Stata v15.2 (StataCorp,
College Station, TX) using the Birmingham BlueBEAR high
performance computer cluster. We present descriptive sta-
tistics, univariable analysis of associations between riskFLA 5.6.0 DTD  YJCGH57705_proof  1factors and incidence, and multivariable analysis with ad-
justments for sex, age, smoking status, Townsend30 depri-
vation quintile, and latitude. Where data were adjusted for
covariables, direct standardization was used. Where direct
standardization was used to adjust for multiple covariables,
individuals with missing data in any category were
excluded. For the examination of trends over time, latitude,
or quintiles of deprivation, a least-squares linear regression
was performed. For assessing for changes in sex ratios, the
chi-squared test for trend was used.
Maps were produced using QGIS v3.49 (https://
www.qgis.org) using public domain shapefiles from the
UK Ordnance Survey OpenData project.
Ethical Approval
THIN previously received approval for research using
its database from the NHS South-East Multi-Centre
Research Ethics Committee in 2003. This study received
approval from the THIN Scientific Review Committee
(reference 16THIN055).
Results
Overall, a total of 8,590,421 pseudonymized patient
records with a total of approximately 53.3 million years
of follow-up evaluation from 694 practices were8 February 2021  6:24 pm  ce DVC
Q20
Q21
Table 1. Incidence per 100,000 per Year of PBC, PSC, and AIH for the Time Period January 1, 2002 to 2016-05-10 Q34
Category Subcategory
PBC PSC AIH
n Incidence 95% CI n Incidence 95% CI n Incidence 95% CI
Population – 1314 2.47 2.33–2.60 396 0.74 0.67–0.82 1034 1.95 1.83–2.07
Latitude 50- 111 1.96 1.57–2.34 42 0.76 0.52–1.00 103 1.80 1.44–2.17
51- 373 1.86 1.67–2.06 135 0.65 0.54–0.75 359 1.75 1.57–1.93
52- 135 1.75 1.45–2.05 68 0.84 0.64–1.05 142 1.76 1.46–2.05
53- 220 2.76 2.40–3.13 60 0.75 0.56–0.94 157 1.97 1.66–2.28
54- 161 4.35 3.66–5.05 29 0.80 0.50–1.10 79 2.18 1.68–2.67
55- 151 4.06 3.31–4.80 33 0.89 0.56–1.22 88 2.35 1.77–2.92
56- 70 4.19 3.13–5.25 9 0.52 0.18–0.86 45 2.45 1.69–3.22
57- 86 4.55 3.52–5.58 18 0.98 0.50–1.46 58 3.06 2.18–3.93
Missing 7 2.36 0.57–4.15 2 0.56 0.00–1.33 3 0.73 0.00–1.57
Sex Male 173 0.66 0.56–0.76 230 0.91 0.79–1.03 241 0.94 0.82–1.06
Female 1141 4.24 3.99–4.49 166 0.59 0.50–0.68 793 2.92 2.72–3.13
Age, y 0–9.9 0 0.00 0.00–0.00 2 0.00 0.00–0.00 7 0.12 0.00–0.26
10–19.9 1 0.01 0.00–0.02 21 0.03 0.01–0.04 55 0.93 0.54–1.32
20–29.9 5 0.07 0.01–0.13 34 0.05 0.03–0.07 48 0.62 0.44–0.81
30–39.9 59 0.71 0.52–0.90 28 0.03 0.02–0.05 87 1.10 0.87–1.34
40–49.9 181 1.94 1.65–2.23 68 0.08 0.06–0.10 132 1.45 1.20–1.70
50–59.9 318 4.10 3.52–4.68 61 0.08 0.06–0.10 221 2.70 2.34–3.07
60–69.9 353 5.08 4.53–5.63 87 0.14 0.10–0.17 239 3.68 3.13–4.23
70–79.9 277 6.22 5.20–7.25 65 0.15 0.10–0.19 181 3.72 3.15–4.29
80–89.9 111 4.28 3.20–5.36 28 0.09 0.05–0.13 61 2.34 1.67–3.00
90 9 1.21 0.38–2.05 2 0.02 0.00–0.05 3 0.71 0.00–1.65
Deprivation 1 (least) 268 2.21 1.91–2.51 99 0.67 0.53–0.81 242 1.85 1.59–2.11
2 287 2.43 2.14–2.72 88 0.74 0.58–0.91 225 1.90 1.65–2.16
3 282 2.60 2.29–2.91 87 0.81 0.64–0.98 219 2.02 1.75–2.29
4 244 2.62 2.28–2.96 69 0.80 0.61–1.00 175 1.95 1.65–2.25
5 (most) 187 2.82 2.35–3.28 39 0.73 0.46–0.99 141 2.25 1.82–2.67
Missing 46 2.86 1.93–3.79 14 0.75 0.35–1.15 32 1.76 1.06–2.45
Smoking Smoker 400 3.40 3.03–3.77 54 0.47 0.33–0.61 256 2.24 1.94–2.55
Ex-smoker 308 2.93 2.58–3.27 69 0.61 0.45–0.77 185 1.98 1.54–2.42
Never smoker 596 1.96 1.80–2.12 265 0.95 0.83–1.07 578 1.96 1.79–2.12
Missing 10 0.87 0.17–1.57 8 0.26 0.00–0.56 15 0.30 0.00–0.64
NOTE. Figures are adjusted for latitude, sex, age, Townsend30 deprivation quintile, and smoking status by direct standardization as appropriate. Figures are per
100,000 population/y with 95% CIs. Deprivation refers to Townsend30 deprivation quintiles. See also Supplementary Table 2 Q35.
AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.




















































































































464examined. The first entry to follow-up was January 1,
2002, and the last data collection point was 2016-05-10.
The median follow-up period was 5.2 years (interquartile
range [IQR], 1.9–10.2 y). A total of 1314 incident cases of
PBC, 396 incident cases of PSC, and 1034 incident cases
of AIH were identified.FLA 5.6.0 DTD  YJCGH57705_proof  1Incidence and Prevalence
The summary details of incident cases are provided in
Supplementary Tables 1 and 2. When assessed by linear
regression, there was no significant change in the inci-
dence of any of PBC, PSC, or AIH over the study period
(Supplementary Table 4 and Supplementary Figure 1).8 February 2021  6:24 pm  ce DVC
Q22
Table 2. Prevalence of PBC, PSC, and AIH in 2015
Category Subcategory
PBC PSC AIH
n Incidence 95% CI n Incidence 95% CI n Incidence 95% CI
Population – 1299 39.62 37.50–41.74 353 10.77 9.65–11.88 1116 34.04 32.06–36.02
Latitude 50- 83 28.16 21.88–34.44 27 9.71 5.87–13.55 93 32.19 25.38–39.00
51- 381 30.59 27.50–33.69 141 10.61 8.84–12.38 382 29.78 26.76–32.79
52- 84 27.29 21.44–33.15 30 9.90 6.29–13.50 88 29.00 22.89–35.10
53- 161 42.01 35.51–48.51 34 8.55 5.64–11.45 143 37.20 31.04–43.37
54- 153 63.86 53.70–74.02 27 11.41 7.09–15.74 98 42.69 34.10–51.30
55- 195 49.79 42.02–57.56 40 10.46 7.01–13.91 148 40.47 33.02–47.93
56- 103 60.95 48.53–73.36 18 10.63 5.67–15.58 71 41.00 31.17–50.82
57- 129 61.08 50.11–72.05 34 16.70 10.77–22.63 88 39.11 30.44–47.78
Missing 10 37.40 15.06–59.74 2 8.51 0.00–19.85 5 18.50 3.98–33.03
Sex Male 143 8.82 7.37–10.28 205 13.25 11.43–15.07 283 17.93 15.83–20.04
Female 1156 69.35 65.36–73.33 148 8.69 7.28–10.09 833 50.36 46.92–53.79
Age 0-9.9 0 0.00 0.00–0.00 1 0.06 0.00–0.18) 2 2.55 0.00–7.43
10-19.9 0 0.00 0.00–0.00 11 3.64 1.40–5.89 28 9.02 4.34–13.68
20-29.9 2 0.77 0.00–1.95 33 7.23 4.14–10.32 67 16.74 10.76–22.71
30-39.9 31 5.88 3.78–7.98 42 8.30 5.72–10.88 82 23.58 14.76–32.40
40-49.9 121 21.04 17.27–24.82 44 9.09 5.44–12.73 132 28.08 18.51–37.65
50-59.9 260 52.81 41.85–63.77 67 12.34 9.36–15.32 201 35.66 30.68–40.65
60-69.9 363 84.44 70.06–98.82 73 15.81 12.07–19.55 279 68.96 55.14–82.77
70-79.9 344 100.97 89.93–112.02 54 19.14 12.56–25.72 221 66.06 56.93–75.20
80-89.9 163 84.97 70.48–99.46 26 12.41 7.34–17.49 97 57.29 44.49–70.10
90þ 15 29.64 13.90–45.37 2 3.38 0.00–7.90 7 33.83 0.96–66.69
Deprivation 1 – least 269 38.15 32.99–43.30 13 9.84 6.14–13.53 233 31.40 26.79–36.00
2 295 43.15 38.50–48.36 88 11.92 9.67–14.69 261 35.87 31.40–40.34
3 268 39.24 34.82–44.24 83 12.14 9.79–15.05 247 36.30 31.77–40.83
4 256 41.82 37.00–47.27 70 10.25 8.11–12.96 189 32.09 27.41–36.78
5 – most 175 40.28 34.74–46.72 64 10.45 8.18–13.36 156 37.31 30.60–44.00
Missing 36 28.32 20.43–39.27 35 8.06 5.78–11.22 30 27.27 16.52–38.03
Smoking Smoker 347 48.60 43.04–4.15 41 5.27 3.54–7.00 273 40.01 34.37–45.66
Ex-smoker 351 52.55 46.96–58.13 60 8.49 6.19–10.80 234 36.33 31.46–41.21
Never smoker 596 31.43 28.89–33.97 247 14.13 12.34–15.93 595 32.73 29.91–35.57
Missing 5 10.69 0.61–20.77 5 3.92 0.00–8.14 14 23.31 8.09–38.55
NOTE. Figures are adjusted for latitude, sex, age, Townsend30 deprivation quintile, and smoking status by direct standardization as appropriate. Figures are per
100,000 population with 95% CIs. Deprivation refers to Townsend30 deprivation quintiles. See also Supplementary Table Q363.
AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.




















































































































580In 2015, the last full year of the study, a total of 1299
prevalent cases of PBC, 353 cases of PSC, and 1116 cases
of AIH were identified. Details of disease prevalence are
summarized in Table 2 and Supplementary Table 3. The
prevalence of all 3 diseases increased over time
(Supplementary Figure 2). Of those prevalent cases ofFLA 5.6.0 DTD  YJCGH57705_proof  1PSC in 2015, 52% had a lifetime diagnosis of ulcerative
colitis, and 15% a lifetime diagnosis of Crohn’s disease.
Latitude
To confirm whether a previously reported correlation
















FLA 5.6.0 DTD  YJCGH57705_proof  1








































































































684set, the incidence of MS was assessed. The overall crude
incidence of MS was 8.98 (8.75–9.23) per 100,000/y.
When assessed by latitude band after adjustment for
sex, age, smoking status, and Townsend30 quintile, there
was a higher incidence of MS in the in the 57 band at
13.67 (11.86–15.48) per 100,000/y than in the 50
latitude band at 8.24 (7.40–9.07) per 100,000/y
(Supplementary Figure 3 and Supplementary Table 5).
There was an increase in MS incidence of 0.66
(0.25–1.07) per 100,000/y per degree in latitude in-
crease (r2 ¼ 0.721; P ¼ .008). By contrast, for hyper-
tension, a disease not reported to have an association
with latitude, overall incidence was 946.26
(943.58–948.94) per 100,000/y with no significant cor-
relation with latitude at -5.02 (-30.27 to 20.23) per
100,000/y per degree in latitude (r2 ¼ 0.038; P ¼ .644)
(Supplementary Figure 3 and Supplementary Table 5).
For AILDs, the crude incidence of PBC was markedly
greater at more northerly latitudes (Table 1,
Supplementary Table 2, Figure 1, Figure 2, and
Supplementary Figure 4). After adjustment for sex, age,
smoking status, and Townsend30 deprivation quintile,
there remained a more than doubling in incidence from
the 1.96 (1.57–2.34) per 100,000/y in the 50 latitude
band to 4.55 (3.52–5.58) per 100,000/y in the 57 lati-
tude band. When assessed by linear regression,
PBC incidence increased by 0.46 (0.27–0.66) per
100,000/y per degree in latitude (r2 ¼ 0.850; P ¼ .001).
Similarly, but less markedly, the incidence of AIH was
greater at more northerly latitudes at 0.19 (0.11–0.26)
per 100,000/y per degree (r2 ¼ 0.873; P < .001).
PSC incidence showed no significant correlation
with latitude at 0.01 (-0.02 to 0.04) per 100,000/y
(r2 ¼ 0.055; P ¼ .577).
In 2015, after adjustment for age, sex, smoking status,
and Townsend30 quintile, there was a significant increase
in the prevalence of both PBC and AIH at more northerly
latitudes; such a gradient was not apparent for PSC
(Table 2, Supplementary Table 3, and Figure 3). The
prevalence of PBC increased by 5.61 (2.61–8.62) per
100,000 per degree of latitude (r2 ¼ 0.777, P ¼ .003). For
PSC, the prevalence did not change significantly at 0.64
(-0.14 to 1.40) per 100,000 per degree of latitude (r2 ¼
0.406, P ¼ .090). For AIH, the prevalence increased by
1.72 (0.36–3.08) per 100,000 per degree of latitude (r2 ¼
0.616, P ¼ .021).=
Figure 2.Maps of the United Kingdom showing the crude
incidence of autoimmune liver diseases. Incidences are for
the whole study period and shown as cases per 100,000/y.
The density of shading corresponds to incidence as denoted
in each panel: (A) primary biliary cholangitis (PBC), (B) primary
sclerosing cholangitis (PSC), and (C) autoimmune hepatitis
(AIH). The locations of major cities are shown for reference.
















































































































































































































Figure 3. Prevalence of autoimmune liver disease by latitude. Top row: Plots denote crude prevalence at the end of 2015 of (A)
primary biliary cholangitis (PBC), (B) primary sclerosing cholangitis (PSC), and (C) autoimmune hepatitis (AIH). (D–F) Bottom
row: Plots denote adjusted incidence after adjustment for sex, age, smoking status, and Townsend30 deprivation quintile. For
PBC, 5.89 (2.51–9.27) per 100,000 per degree (r2 ¼ 0.752; P ¼ .005); PSC, 0.62 (-0.18 to 1.41 Q33) per 100,000 per degree (r2 ¼
0.375; P ¼ .107); and AIH, 1.92 (0.150–3.69) per 100,000 per degree (r2 ¼ 0.540; P ¼ .038).

































































































793Given the apparent differences in incidence between
latitude bands, patient sex and age at presentation were
assessed by latitude band. There was a significant trend
toward the younger incidence of AIH at more northerly
latitudes (-0.87; -1.49 to -0.25) years per degree (r2 ¼
0.663, P ¼ .014), but no significant difference in age for
incident PBC or PSC, and no significant difference in
incident sex ratios in any disease (Supplementary
















Over the whole study period, 1141 (86.8%) incident
cases of PBC were female, with a female:male ratio of
6.6:1; for PSC, 230 (58.1%) were male, with a 1.4:1
male:female ratio; for AIH, 793 (76.6%) were female,
with a female:male ratio of 3.3:1. There was no signifi-
cant change in the sex ratio of incident cases over time
for any of the conditions (Supplementary Table 8). The
median age of incident PBC was 63 years (IQR, 53–72 y);
for PSC the median age was 57 years (IQR, 43–69 y); and
for AIH the median age was 58 years (IQR, 44–69 y). The
age of incidence did not change for PBC and PSC over the
study period, but for AIH the median age at incidence
increased (Supplementary Table 9).FLA 5.6.0 DTD  YJCGH57705_proof  1Smoking
After adjustment for sex, age, Townsend30 depriva-
tion quintile, and latitude, incident PBC was more
frequent in smokers than those who had never smoked
at 3.40 (3.03–3.77) per 100,000/y and 1.96 (1.80–2.12)
cases per 100,000/y, respectively. After the same ad-
justments, there was a lower incidence of PSC in smokers
0.47 (0.33–0.61) per 100,000/y compared with those
who had never smoked 0.95 (0.83–1.07) per 100,000/y.
For AIH, there was no difference between current
smokers and those who had never smoked.Deprivation
PBC was associated significantly with deprivation.
The incidence was 2.21 (1.91–2.51) per 100,000/y, and
in the most deprived quintile the incidence was 2.82
(2.35–3.28) per 100,000/y after adjustment for age, sex,
latitude, and smoking status. When assessed by linear
regression, there was an increase in incidence of 0.14
(0.08–0.20) per 100,000/y per Townsend30 quintile
(r2 ¼ 0.946; P ¼ .005). The incidence of PSC and AIH did
not vary significantly with deprivation; deprivation var-













































































Data on ethnicity were missing for 5,008,804 (58.3%)
registrations and a similar proportion of those diagnosed
with AILD (Supplementary Tables 2 and 3). Among the
minority with a recorded ethnicity, the crude incidence
and prevalence of PBC among those of white ethnicity
was greater than in those of non-white ethnicities. For
PSC and AIH, there were no significant differences. At-
tempts to adjust for covariables were not made because















































In this study we used aggregate data from a nation-
ally representative cross-section of primary care prac-
tices to show markedly greater incidences of both PBC
and AIH at more northerly latitudes. For PBC there was a
greater than doubling of incidence over 7o of latitude; for
AIH there was an increase of more than 50%. These
observations persisted after correction for sex, age,
deprivation, and smoking status. For PBC, the difference
was notable for being more marked than the fold change
in incidence for MS in either this study or in meta-ana-
lyses.24,25 This observation may help future in-
vestigations of the etiopathogenesis in PBC and AIH and
may explain some missing disease risk and variation
between our study and other studies.
One potential explanation for a disease correlation with
latitude is varying sunlight (ultraviolet light) exposure and
its effects on vitamin D metabolism. Such a pathway has
been proposed in PBC previously.21,34 However, if this were
a major etiologic factor, patients with more pigmented skin
might be expected to be at increased risk.35 Perhaps dif-
ferences in sunlight exposure modulate genetic risk. In
addition, it is unclear as to what stage in life any exposure
effect from differing latitudes may occur and it is plausible
that it is childhood exposure that is most important.26
Expanding this work to other geographic areas is neces-
sary. Equally, looking for similar correlations in disease
incidence and latitude in other diseases associated with low
vitamin D status such as inflammatory bowel disease would
be valuable.36 In addition, environmental factors other than
vitamin D may be important. Smoking correlates with both
PBC and AIH incidence and it may be that our study has
undercorrected for these. Other environmental toxins that
have been proposed include toxic waste, coal, and hair
dye.10,37,38 It is unknown as to how these might correlate
with latitude. It is equally possible that some previously
unconsidered factor perhaps relating to geology, diet, local
flora, or air quality is responsible for these results. In
addition, the genetic make-up of the United Kingdom varies
significantly with geography and it may be that our results
reflect an unrecognized genetic tendency.39
Two other observations within our results warrant
discussion in the context of others’ work. First, we have
shown no correlation between PSC and latitude, whereasFLA 5.6.0 DTD  YJCGH57705_proof  1a high prevalence of PSC has been reported in the Nordic
countries, which are at northern latitudes.40 Some of this
risk, however, may be genetic.41 In addition, the Nordic
countries have low rates of smoking and are prosperous.
Notably, studies from Canada, which is also at a relatively
northerly latitude, do not record disproportionately high
rates of PSC.5 Second, we recorded a lower median age at
presentation among patients with AIH at more northern
latitudes in our cohort. Although this may correlate with
exposure to an unknown environmental factor, it also
may relate to genetic predisposition in the context of
known marked geographic genetic variations in the
United Kingdom.39 Variations in age of presentation in
relation to HLA-D haplotype are well recognized in AIH,
as are variations in age of presentation internationally.3
To consider both questions more fully, additional
studies with consistent approaches to diagnosis based
over large and varying geographic areas are required.
Our estimates for incidence are close to those reported
elsewhere: in a recent meta-analysis, the population inci-
dence of PSC across a number of countries was estimated
at 0 to 1.3 per 100,000/y, and at 0.33 to 5.8 per 100,000/y
for PBC.5 By comparison, in this study the overall incidence
was calculated at 0.74 per 100 000/y and 2.47 per
100,000/y, respectively. For AIH, meta-analyses are lack-
ing, but 2 recent studies from Europe reported incidences
of 1.1 per 100,000/y and 1.7 per 100,000/y; we report an
incidence of 1.94 per 100,000/y.6,7 Our overall prevalence
estimates also are similar to those published elsewhere.
There are likely to be differences in this cohort compared
with others. We reported median ages for the diagnosis of
AILD that are higher than those reported elsewhere. For
example, the median age at diagnosis of PBC in our cohort
was 63 years; in the UK-PBC national cohort the median age
was 55 years.42 For PSC, our median age was 57 years, the
International PSC Study Group reported a mean age at
diagnosis of 39 years.43 Such differences may reflect age-
associated differences in referral patterns to, or retention of
follow-up evaluation in, secondary care; bias in entry into
registries; or differences in diagnostic classification between
primary and secondary care. Furthermore, our work only
examined adults, whereas the International PSC Study Group
cohort, for example, contained 13% of individuals aged
younger than 20. Our work has shown an apparent nar-
rowing in the female:male ratio of patients referred for
transplantation in PBC.4 In this study, there was no change
over time in the sex ratio for any disease including PBC. This
may reflect the reported poorer outcome for men than
women diagnosed with PBC, an observation that in turn has
been related to later diagnosis.42
In this study we confirm the previously identified
dichotomous effect of smoking on AILD risk by showing
an association with increased incidence of both PBC and
AIH, but with decreased PSC risk. Notably, these associ-
ations persisted after controlling for deprivation, which
may be associated with smoking behavior.44 We note
negative national trends in smoking over our study
period, although this study was not powered to show8 February 2021  6:24 pm  ce DVC
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1044differences in the duration of exposure and time from
exposure that might be expected to affect future AILD
epidemiology as national smoking trends change.45
Ethnicity, with its potential associations with both
genetics and environment, remains an incompletely un-
derstood component of AILD risk. Interpreting the role of
ethnicity and disease risk in this study was hampered by
a large proportion of individuals not having a recorded
ethnicity and there being relatively few patients of non-
white ethnicities. However, we do describe an approxi-
mately doubled incidence of PBC in those of white
ethnicity as compared with those of other ethnicities.
Such an association has been described elsewhere, but
this large cohort underlines such differences.46 We are
unable to comment on differences in the likelihood of
investigation for PBC in these populations or on disease
trajectory or severity at diagnosis described by others.47
This study had several strengths: its 14-year time
frame, large cohort size, the presence of information about
co-factors, and its derivation from primary care records
rather than secondary care records avoided the inherent
risk of selection bias in the latter. Potential weaknesses of
this study include the possibility of inaccurate recording of
diagnoses. We note, however, work suggesting that at least
for AIH, primary care Read codes are broadly represen-
tative of specialist diagnoses.31 Furthermore, although we
have corrected for a major measure of socioeconomic
grouping by using Townsend30 quintiles, we may have not
corrected sufficiently and some of the gradient in inci-
dence we are seeing may reflect factors associated with
this such as dietary habits, exposure to environmental
toxins, or access to health care. In addition, we may have
underestimated the incidence of these diseases because of
our exclusion of overlapping disease and incident disease
within 1 year of joining a general practice. We cannot
exclude the existence of an alternative confounding factor
in relation to genetics, the environment, or medical prac-
tice that would explain the variations in PBC and AIH seen
at different latitudes. We note specifically the existence of a
center with a particular focus on AILDs in Newcastle in the
54 latitude band. Our findings require confirmation in a
different geographic region. A high proportion of in-
dividuals did not have ethnicity recorded, meaning that
this was excluded from analysis and ethnicity represents a
further potential confounder. Finally, we were unable to
account for previous places of residence for individuals
who had changed location over time.
Here, we show a striking correlation between
increased geographic latitude and disease risk for PBC;
the same phenomenon is present to a lesser extent for
AIH, but absent for PSC. We also present key de-
mographic information with regards to sex, age, depri-
vation, and smoking status derived from primary care
data. Our results support a new avenue of investigation
in AILD etiology, provide primary care–derived estimates
of AILD epidemiology, and confirm others’ findings
regarding the environmental impact of smoking, depri-
vation, and ethnicity on the AILDs.FLA 5.6.0 DTD  YJCGH57705_proof  1Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2021.01.029.8 FebReferences
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